• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一些炎症参数能否预测恶性胸腔积液患者的生存期?

Can some inflammatory parameters predict the survival of patients with malignant pleural effusion?

作者信息

Dilvin Ozkan Nur, Bas Aynur, Scheed Axel, Vogl Melanie, Bohanes Tomas, Stubenberger Elisabeth, Sayan Muhammet, Cuneyt Kurul Ismail, Bahil Ghanim, Celik Ali

机构信息

Department of Thoracic Surgery, Milas State Hospital, Muğla, Türkiye.

Department of Thoracic Surgery, Başakşehir Çam Sakura City Hospital, İstanbul, Türkiye.

出版信息

Turk Gogus Kalp Damar Cerrahisi Derg. 2024 Oct 30;32(4):445-452. doi: 10.5606/tgkdc.dergisi.2024.26905. eCollection 2024 Oct.

DOI:10.5606/tgkdc.dergisi.2024.26905
PMID:39651046
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11620533/
Abstract

BACKGROUND

This study aimed to investigate whether there is a correlation between some serum inflammatory markers and the survival of patients with malignant pleural effusions (MPEs).

METHODS

The prospective study included 125 patients (67 males, 58 females; median age: 62 years; range, 40 to 92 years) who underwent thoracentesis for pleural effusion between January 2020 and December 2021. An overall survival analysis was performed, and survival differences between the groups were investigated. The cutoff value of the inflammatory parameters associated with mortality was determined by receiver operating characteristic analysis.

RESULTS

Median survival after detection of MPE was six months, and three- and five-year overall survivals were 16% and 4%, respectively. There was a significant correlation between the ECOG (Eastern Cooperative Oncology Group) score of the patients and the median survival. Serum C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), fluid albumin, and serum lactate dehydrogenase (LDH)-to-pleural LDH ratio and survival had a statistically significant relationship in receiver operating characteristic analysis. Threshold values were determined accordingly. Poor prognostic factors that were found to be statistically significant were high CRP (p=0.001), high NLR (p=0.001), high PLR (p=0.02), and high serum LDH-to-pleural LDH ratio (p=0.04).

CONCLUSION

Some serum inflammatory markers, including high CRP, high NLR, high PLR, and high serum LDH-to-pleural LDH ratio, can be a simple and inexpensive method in predicting prognosis in patients with MPE.

摘要

背景

本研究旨在调查某些血清炎症标志物与恶性胸腔积液(MPE)患者生存率之间是否存在相关性。

方法

这项前瞻性研究纳入了2020年1月至2021年12月期间因胸腔积液接受胸腔穿刺术的125例患者(67例男性,58例女性;中位年龄:62岁;范围40至92岁)。进行了总生存分析,并研究了各组之间的生存差异。通过受试者工作特征分析确定与死亡率相关的炎症参数的临界值。

结果

检测到MPE后的中位生存期为6个月,3年和5年总生存率分别为16%和4%。患者的东部肿瘤协作组(ECOG)评分与中位生存期之间存在显著相关性。在受试者工作特征分析中,血清C反应蛋白(CRP)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、胸水白蛋白以及血清乳酸脱氢酶(LDH)与胸水LDH比值与生存具有统计学显著关系。相应地确定了阈值。发现具有统计学显著性的不良预后因素为高CRP(p=0.001)、高NLR(p=0.001)、高PLR(p=0.02)和高血清LDH与胸水LDH比值(p=0.04)。

结论

一些血清炎症标志物,包括高CRP、高NLR、高PLR和高血清LDH与胸水LDH比值,可作为预测MPE患者预后的一种简单且廉价的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/1e8bd8549e8b/TJTCS-2024-32-4-445-452-F7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/c46d15b4ecf5/TJTCS-2024-32-4-445-452-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/c09ef2fe5a9f/TJTCS-2024-32-4-445-452-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/e17fa04b7b69/TJTCS-2024-32-4-445-452-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/f03030788401/TJTCS-2024-32-4-445-452-F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/1a3c992adbea/TJTCS-2024-32-4-445-452-F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/3f1332608de0/TJTCS-2024-32-4-445-452-F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/1e8bd8549e8b/TJTCS-2024-32-4-445-452-F7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/c46d15b4ecf5/TJTCS-2024-32-4-445-452-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/c09ef2fe5a9f/TJTCS-2024-32-4-445-452-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/e17fa04b7b69/TJTCS-2024-32-4-445-452-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/f03030788401/TJTCS-2024-32-4-445-452-F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/1a3c992adbea/TJTCS-2024-32-4-445-452-F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/3f1332608de0/TJTCS-2024-32-4-445-452-F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/11620533/1e8bd8549e8b/TJTCS-2024-32-4-445-452-F7.jpg

相似文献

1
Can some inflammatory parameters predict the survival of patients with malignant pleural effusion?一些炎症参数能否预测恶性胸腔积液患者的生存期?
Turk Gogus Kalp Damar Cerrahisi Derg. 2024 Oct 30;32(4):445-452. doi: 10.5606/tgkdc.dergisi.2024.26905. eCollection 2024 Oct.
2
Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?LENT 预后评分(LDH、ECOG 体能状态评分、血中性粒细胞/淋巴细胞比值、肿瘤类型)能否改变恶性胸腔积液的临床处理方法?
Tuberk Toraks. 2021 Jun;69(2):133-143. doi: 10.5578/tt.20219802.
3
Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion.使用血清碱性磷酸酶和胸腔积液乳酸脱氢酶的新评分对恶性胸腔积液患者的预后价值。
Thorac Cancer. 2020 Feb;11(2):320-328. doi: 10.1111/1759-7714.13262. Epub 2019 Dec 13.
4
Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.一种利用血清中性粒细胞与淋巴细胞比值和恶性胸腔积液对肺癌患者进行预后评估的新评分方法的预后影响。
BMC Cancer. 2017 Aug 22;17(1):557. doi: 10.1186/s12885-017-3550-8.
5
Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance.恶性胸腔积液中性粒细胞与淋巴细胞比值:预后意义。
PLoS One. 2021 Apr 26;16(4):e0250628. doi: 10.1371/journal.pone.0250628. eCollection 2021.
6
Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion.升高的预处理血小板与淋巴细胞比值与伴恶性胸腔积液的 IV 期非小细胞肺癌患者的不良生存相关。
Sci Rep. 2019 Mar 18;9(1):4721. doi: 10.1038/s41598-019-41289-9.
7
Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?治疗前中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值对预测小细胞肺癌患者的预后是否有用?
Oncotarget. 2017 Jun 6;8(23):37200-37207. doi: 10.18632/oncotarget.16553.
8
Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.影响非小细胞肺癌伴恶性胸腔积液患者生存的预后因素。
Clin Respir J. 2016 Nov;10(6):791-799. doi: 10.1111/crj.12292. Epub 2015 Apr 15.
9
Malignant pleural effusions in lymphoproliferative disorders.淋巴增生性疾病中的恶性胸腔积液
Leuk Lymphoma. 2005 Jul;46(7):1039-44. doi: 10.1080/00268970500096616.
10
Platelet-to-Lymphocyte Ratio and Survival in Malignant Pleural Effusion.血小板与淋巴细胞比值及恶性胸腔积液患者的生存率
Clin Lab. 2020 Aug 1;66(8). doi: 10.7754/Clin.Lab.2020.191267.

本文引用的文献

1
Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis.基线C反应蛋白水平与接受免疫治疗的癌症患者生存结局之间的关联:一项荟萃分析。
Exp Ther Med. 2023 Jun 8;26(2):361. doi: 10.3892/etm.2023.12060. eCollection 2023 Aug.
2
The prognostic role of lymphocyte to monocyte ratio (LMR) in patients with Myelodysplastic Neoplasms.淋巴细胞与单核细胞比值(LMR)在骨髓增生异常肿瘤患者中的预后作用。
Hematology. 2023 Dec;28(1):2210929. doi: 10.1080/16078454.2023.2210929.
3
Elevation of C-reactive protein during concurrent chemoradiotherapy is a poor predictive factor for head and neck cancer.
同期放化疗期间 C 反应蛋白升高是头颈部癌症不良的预测因素。
Auris Nasus Larynx. 2023 Aug;50(4):601-606. doi: 10.1016/j.anl.2022.12.014. Epub 2023 Jan 3.
4
Tumor-associated neutrophils and neutrophil-targeted cancer therapies.肿瘤相关中性粒细胞与针对中性粒细胞的癌症治疗
Biochim Biophys Acta Rev Cancer. 2022 Sep;1877(5):188762. doi: 10.1016/j.bbcan.2022.188762. Epub 2022 Jul 16.
5
Diagnosis and Management of Malignant Pleural Effusion: A Decade in Review.恶性胸腔积液的诊断与管理:十年回顾
Diagnostics (Basel). 2022 Apr 18;12(4):1016. doi: 10.3390/diagnostics12041016.
6
Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis.外周全血细胞计数衍生指标(中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、淋巴细胞与单核细胞比值/单核细胞与淋巴细胞比值)在多发性骨髓瘤中是具有临床意义的预后生物标志物吗?一项系统评价与荟萃分析。
Front Oncol. 2021 Nov 23;11:766672. doi: 10.3389/fonc.2021.766672. eCollection 2021.
7
Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?LENT 预后评分(LDH、ECOG 体能状态评分、血中性粒细胞/淋巴细胞比值、肿瘤类型)能否改变恶性胸腔积液的临床处理方法?
Tuberk Toraks. 2021 Jun;69(2):133-143. doi: 10.5578/tt.20219802.
8
Preoperative lymphocyte-to-monocyte ratio (LMR) could independently predict overall survival of resectable gastric cancer patients.术前淋巴细胞与单核细胞比值(LMR)可独立预测可切除胃癌患者的总生存期。
Medicine (Baltimore). 2018 Dec;97(52):e13896. doi: 10.1097/MD.0000000000013896.
9
ERS/EACTS statement on the management of malignant pleural effusions.ERS/EACTS 声明:恶性胸腔积液的处理。
Eur J Cardiothorac Surg. 2019 Jan 1;55(1):116-132. doi: 10.1093/ejcts/ezy258.
10
Prognostic Factors of 30-day Survival of Patients with Malignant Pleural Effusion.恶性胸腔积液患者30天生存的预后因素
Indian J Palliat Care. 2017 Jul-Sep;23(3):321-324. doi: 10.4103/IJPC.IJPC_2_17.